Novartis' (NVS.US) "potential blockbuster" oral new drug application for a new indication in China
Thursday, Sep 5, 2024 9:30 am ET
1min read The National Medical Products Administration's (NMPA) Center for Drug Evaluation's (CDE) website has recently announced that Novartis (NVS.US) has received approval for its new indication application for ipicopan capsules. The specific indication has not been disclosed. Ipicopan is a specific oral complement factor B inhibitor. It was approved for its first indication in China in April this year, used to treat adult patients with paroxysmal nocturnal hemoglobinuria (PNH). This is the third application for the product in China, and public information speculates that the indication may be C3 glomerulopathy.
Disclaimer: the above is a summary showing certain market information. AInvest is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from a third party source. Communications displaying market prices, data and other information available in this post are meant for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.